Advanced ODT Technologies for Drug Development in Japan and the US
CMIC Group will present a complimentary webinar “Advanced ODT Technologies for Drug Development in Japan and the US” on April 11, 2019 (Thursday) at 11am EDT / 8am PDT / 4pm BST.
Since its introduction in the 1980s, the market of orally disintegrating tablet (ODT) has grown annually and ODTs are now available in a variety of therapeutic areas, both over-the-counter (OTC) and by prescription. ODT market is projected to reach US$21B in 2023.
In this webinar, CMIC and Aprecia experts will talk about advanced ODT technologies and its advantages in drug development.
● ODT market trend in Japan and the US
● ODT drug development in Japan
● 3D printing technology
This webinar will be sponsored by CMIC Group. CMIC Group is the first and largest CRO in Japan with extended services in drug development and GMP manufacturing in the US, Japan and Asia.
Click here to register.
Executive Vice President, CMIC HOLDINGS Co.,Ltd.
Representative Director & CEO, CMIC CMO Co., Ltd.
Mr. Makoto Matsukawa is the Representative Director & CEO of CMIC CMO Co. Ltd., a company focusing on CDMO business in CMIC Group. He started the first 15 years of his career at pharmaceutical and medical device companies, such as Baxter Healthcare. Mr. Matsukawa joined CMIC Group in 2012 as an executive officer for Corporate Planning and IPD business. He continues to expand the CDMO business with his broad experience and expertise.
Motokazu Iwata, Ph.D.
Pharmaceutical Development Center, CMIC CMO Co., Ltd.
Dr. Motokazu Iwata joined the Pharmaceutical Development Center at CMIC CMO in 2014. After serving as a general manager, he currently works as a scientific fellow. Prior to joining CMIC CMO, Dr. Iwata worked in the formulation R&D field for more than 30 years in Sumitomo-Dainippon Pharma Co., Ltd., one of the major pharmaceutical companies in Japan. Taking in his expertise, he is now involved in fostering researchers and further expanding the technology platform of CDMO business.
Timothy S. Tracy, Ph.D.
Chief Executive Officer, Aprecia Pharmaceuticals, LLC
Dr. Timothy S. Tracy is the Chief Executive Officer for Aprecia Pharmaceuticals, LLC since January 2018. An expert in clinical pharmacology and a Fellow with the American Association of Pharmaceutical Scientists, Dr. Tracy holds two patents related to drug delivery systems and has published over 100 scientific manuscripts. Dr. Tracy’s research interests deal with pharmacogenetics and their effect on drug metabolism, as well as the larger field of clinical pharmacology.